JPH0418401A - Polysaccharide and anti-ulcer drug containing polysaccharide as active ingredient - Google Patents

Abstract

NEW MATERIAL:A polysaccharide. properties: white and fibrous; molecular weight: 63000 (measured by gel-filtration chromatography) ; constituting sugar: rhamnose, arabinose, xylose, mannose, galactose, glucose and galacturonic acid; uniformity: exhibits in measuring of electrophoresis or gel-filtration chromatography, etc.; bonding form of constituting sugars: 4-bonding galacturonic acid and 2,4-branched galacturonic acid are principal bonding forms and, in addition, composed of terminal arabinofuranose, terminal arabinopyranose, 4-bonding arabinose, 3,4-branched arabinose, 4-bonding xylose, terminal rhamnose, terminal fucose, 4-bonding galactose, terminal galactose or terminal galacturonic acid, etc. USE:Used as an anti-ulcer drug. PREPARATION:For instance, root of Bupleurinum falcatum belonging to Ammiaceae is extracted with an aqueous solvent and said extract solution is subjected to isolation and purification treatment by a well-known method such as precipitation or dialysis.

Description

DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a polysaccharide that has an antiulcer effect and is useful as a pharmaceutical agent such as an antiulcer agent.

[Prior Art and Problems] In recent years, the number of peptic ulcers caused by stress, stimulation by drugs, excessive secretion of gastric acid, etc. has been increasing, and antacids, anticholinergic drugs, and histamine H5 are used to treat this. Development of receptor antagonists, etc. is progressing. However, these drugs have not reached the level of ideal and excellent drugs from the point of view of completely curing ulcers.

Therefore, there is a need for substances with better anti-ulcer effects.

[Means for Solving the Problems] As a result of intensive studies to solve the above problems, the present inventors discovered that a polysaccharide having the following properties has an excellent anti-ulcer effect. It was completed.

That is, the present invention is as shown below.

(1,) The following physical and chemical properties ■Property: white fibrous, ■Molecular weight 63,000 (gel filtration chromatography), ■Specific rotation α]! Mo-+199.7"■ Constituent sugars: rhamnose, arabinose, quinolose, mannose, galactose, glucose, galacturonic acid, ■Unity: Uniformity is shown by electrophoresis, gel filtration chromatography, high performance liquid chromatography, ■Constitution Sugar binding mode: 4-linked galaculronoic acid, 2.4-branched galacturonic acid as the main bonding mode, in addition to this, terminal arahinofuranose, terminal arahinopyranose, 4- or 5-linked arahinose, 3,4- or 3,5-branched arabinose, 4 or 5
linked quinolose, terminal rhamnose, 2-linked rhamnose,
3-linked rhamnose, 3.4-branched rhamnose, 2,4-branched rhamnose, terminal fucose, 4-linked glucose, terminal galactose, 4-linked galactose, 3-linked galactose, 4.6-branched galactose, terminal calacturonic acid, 3.
It is composed of 4- or 3.5-branched galacturonic acid.

(hereinafter referred to as polysaccharide A).

(2) The following physical and chemical properties ■Properties: Light brown fibrous, ■Publication: so, o o ~ 2+, 000° (high performance liquid chromatography) ■Constituent sugars Mainly arabinose and galacturonic acid, with a small amount Rhamnose, quinolose, mannose, glucose.

The polysaccharide having this is hereinafter referred to as polysaccharide B. ) as an active ingredient.

(3) The following physical and chemical properties ■Properties White fibrous, ■Molecular weight 59,000, (gel filtration chromatography) ■Mainly composed sugar galacturonic acid, small amounts of arabinose, galactose, rhamnose, crucose, and trace amounts of xylose and mannose .

An anti-inflammatory agent containing a polysaccharide having the following (hereinafter referred to as polysaccharide C) as an active ingredient.

(4) The following physical and chemical properties ■Properties: Light brown fibrous, ■Molecular 1! :28 000, (Gel filtration chromatography) ■ Constituent sugars: Mainly galacturonic acid, small amounts of arabinose, galactose, rhamnose, and trace amounts of quinolose, glucose, and mannose.

An anti-ulcer agent whose active ingredient is a polysaccharide having the following properties (hereinafter referred to as polysaccharide).

(5) The following physical and chemical properties: ■Property light brown fibrous, ■Molecular weight nia 0,000-16,000, (Kell filtration chromatography) ■Mainly composed of sugars arabinose, glucose, and galacturonic acid,
Small amounts of rhamnose and galactose.

The polysaccharide that produces this is hereinafter referred to as polysaccharide E. ) is an anti-cancer agent, and 1 is an anti-cancer agent.

(6) The following physical and chemical properties ■Properties White fibrous, ■Molecular weight: 36,000, (gel filtration chromatography) ■Specific rotation, [α]2z-+120°■Constituent sugars: rhamnose, arabinose, galactose,
Galacturonic acid, ■ Uniformity is shown by electrophoresis, gel filtration chromatography, and high performance liquid chromatography. ■ Constituent sugar binding mode l 5-linked arahinofuranose 14% terminal caractose 27% terminal galacturonic acid
2.7% 35-branched arahinofuranose 2.8%
2.4-branched rhamnose 2.2% 1.4-linked galacturonic acid 800% 16-linked galactose
1.9% 14-linked caractose 4.
An anti-ulcer agent containing a polysaccharide containing 2%, 3.6-branched galactose and 0.7% (hereinafter referred to as polysaccharide F) as an active ingredient.

(7) The following physical and chemical properties ■Properties White fibrous, ■Molecular weight 63,000, (gel filtration chromatography) ■Specific rotation, [α] 2 paleo-199,7゜■ Constituent sugars rhamnose, arabinose, quinocous , Mannose, Calactose, Glucose, Galacturonic acid, ■ Uniformity is shown by electrophoresis, gel filtration, and high-performance liquid chromatography. ■ Constituent sugar binding mode: 4-linked galacturonic acid, 2,4-branched galacturonic acid. In addition, the main bonding modes include terminal arahinofuranose, terminal arabinopyranose, 4 or 5 linked arahinose, 3.4 or 3.5 branched arabinose, 4 or 5
linked quinolose, terminal rhamnose, 2-linked rhamnose,
3-linked rhamnose, 3.4-branched rhamnose, 2.4-branched rhamnose, terminal fucose, 4-linked glucose, terminal galactose, 4-linked galactose, 3-linked galactose, 4.6-branched galactose, terminal calacturonic acid, 3.
It is composed of 4- or 3,5-branched galacturonic acid.

An anti-ulcer agent whose active ingredient is a polysaccharide having

Polysaccharide A has the properties shown above, and since there have been no publications regarding polysaccharides like the one mentioned above, polysaccharide A is recognized as a novel polysaccharide. .

Furthermore, polysaccharides B, C, D, E, and F are known substances that have been isolated by the present inventors.

Polysaccharides A, B, C, D, E, and F can be obtained, for example, from the root of the Apiaceae family, or this root has been used medicinally as the crude drug saiko since ancient times, and its effects include central depressant action and liver damage. It is known to have ameliorating effects, anti-inflammatory effects, etc. Regarding the anti-ulcer activity of Saiko, a weak anti-ulcer activity has been recognized in the saponino fraction of Saiko, but its active ingredients have not been clarified [Shibata et al., Pharmaceutical Journal, 9
31660 (1973) II.

Polysaccharides A, BSC, D, E and F can be obtained, for example, as follows.

- Grind the saiko, the original plant Minomasaiko, or other congenerous plants, extract with an aqueous solvent of about 10 times the volume, filter the extract, centrifuge the filtrate, and freeze-dry the supernatant. Obtain dry matter. This dried material is mixed with acetonate, methanol,
Dissolve in an organic solvent such as ethanol, reflux in some cases, centrifuge to remove lipid components, dissolve the precipitate in purified water, further dialyze, and freeze-dry the non-dialyzed material. Obtain the crude fraction.

Dissolve this crude fraction in purified water, add quaternary ammonium such as cetyl-trimethyl bromide, and mix.
After standing, centrifuge to obtain a precipitate.

■Dissolve the precipitate in a 5-30% aqueous sodium chloride solution, add ethanol, and centrifuge to obtain a precipitate.Dissolve the precipitate in purified water, perform dialysis, and freeze-dry the non-dialysed material. Obtain a polysaccharide-containing fraction.

(2) The supernatant is made to have a pH of 868-95 by adding an aqueous boric acid solution and an alkali such as sodium hydroxide, then left to stand, centrifuged, and the procedure of removing the supernatant is repeated about 2 to 3 times. After neutralizing the resulting supernatant by adding acetic acid, ethanol is added and centrifuged. The precipitate obtained by centrifugation is further dissolved in distilled water, dialyzed, and the non-dialyzed fraction is freeze-dried to obtain a polysaccharide-containing fraction.

The polysaccharide disclosed by the present invention can also be obtained by subjecting the polysaccharide-containing fraction obtained in (1) or (2) to commonly used ion exchange chromatography.

The aqueous solvent for extraction is preferably water, especially purified water, and hot extraction is preferred for extraction.

The conditions for centrifugation are 6,000-s, oo.

rpm, about 20 to 40 minutes is sufficient.

Dialysis may be performed for about 2 to 5 days using running water or purified water.

A specific example of a gel for ion exchange chromatography is DEAE-Sepharose CL.
-6B etc. are mentioned.

Next, specific examples of the production of polysaccharides B, C, D, E and F will be shown.

Specific Example 1 Add 1 (l) of purified water to 1.0 kg of Saiko, heat and extract until the liquid volume becomes half the volume. Filter the extract, and remove the filtrate from 7
Centrifugation was performed at 50 rpm for 30 minutes to obtain a supernatant. Repeat the same operation as above for the precipitate, combine the supernatant, freeze-dry it, dissolve the dried noni powder in methanol, reflux, centrifuge, and dissolve the precipitate in purified water. Thereafter, dialysis was performed against running water for 3 days and against purified water for 2 days.

The non-dialyzed fraction was lyophilized to obtain 1 piece of polysaccharide B35.39.

Specific Example 2 Polysaccharide 1589 obtained in Specific Example 1 was dissolved in purified water, and the same amount of 8% cetyl-trimethyl-ammonium bromide was added.
Mix and leave at 20°C for 4 hours.

This solution was centrifuged, and the precipitate was dissolved in 10% sodium chloride aqueous solution, and ethanol was added and centrifuged. After dissolving the obtained precipitate in purified water,
The resulting non-dialyzed fraction was lyophilized to obtain 54 g of polysaccharide C3.

Specific Example 3 Polysaccharide 1589 obtained in Specific Example 1 was dissolved in purified water, and the same amount of 8% cetyl-trimethyl-ammonium bromide was added.
The mixture was mixed and left at 20°C for 4 hours.

This solution was centrifuged, 1% boric acid was added to the supernatant, 2N sodium hydroxide was added to adjust the pH to 88, and the resulting precipitate was obtained by centrifugation.

This precipitate was mixed with 05% sodium borate buffer p+,
-188), then dissolved in 2% acetic acid, and 5 times the amount of ethanol of this solution was added together with potassium acetate to obtain a precipitate. After centrifugation, the resulting precipitate was further
After repeated washing with ethanol containing % acetic acid and ethanol, it was dissolved in distilled water. After dialyzing this solution, the internal solution was freeze-dried to reduce the polysaccharide content to 25% per crude polysaccharide.
% yield was obtained.

Specific example 4 Polysaccharide obtained in specific example 1 15.8? was dissolved in purified water, the same amount of 8% cetyl-trimethyl-ammonium bromide was added, mixed and left at 20°C for 4 hours.

This solution was centrifuged, 1% boric acid 790- was added to the supernatant, and 2N sodium hydroxide was added to make p) 188,
After centrifugation, 2N sulfur and lithium hydroxide was added to the supernatant to adjust the pH to 9.5, followed by further centrifugation. Ethanol was added to the thus obtained supernatant, the resulting precipitate was dissolved in purified water, and then dialyzed against purified water, and the resulting non-dialyzed fraction was lyophilized to obtain polysaccharide E5. I got 91@.

Specific Example 5 The polysaccharide 500 R' obtained in Specific Example 2 was dissolved in purified water, equilibrated with purified water, and adsorbed on an E A E Sepharose CL6B column, using an ammonium hydrogen carbonate solution as a solvent. Elute by changing the concentration sequentially f2.

After dialysis of the eluate against distilled water by elution with 0.3M ammonium hydrogen carbonate, the dialyzed solution was concentrated and further diluted with 0,2
M Sepharose equilibrated with sodium chloride C1, -
Kerl filtration was performed using a 6B column to obtain polysaccharide F165j19.

Next, the fact that polysaccharides A, B, C, D, E, and F have anti-ulcer effects and are useful as anti-ulcer agents will be explained using experimental examples.

For the experiment, ICR male mice (body weight at the time of use, approximately 35 mm) were used.
~40g) or Wistar (%'1star) male rats (weight 170-200g at time of use) were used. These mice were purchased from SLC and preliminarily reared for one week in a breeding room. In addition, before use, the animals were fasted for a certain period of time using a metal cage with a mesh bottom.

Experimental Example 1 Polysaccharide 100119/9 obtained in the specific examples or examples was orally administered to mice fasted for 24 hours.

Fifty minutes later, hydrochloric acid-ethanol (60% ethanol containing 03-hydrochloric acid) was orally administered at a dose of 0.2 d/mouse. One hour later, the mice were killed by tibial dislocation, the stomach was removed, and physiological saline 2- was injected into the stomach, and 5%
The specimen was immersed in a formalin solution for 30 minutes and lightly fixed (hereinafter, this operation is referred to as formalin treatment). The stomach was incised along the human surface, the length of each injury (hemorrhagic erosion) occurring in the glandular stomach was measured, and the total sum per animal was taken as the injury coefficient and compared with the control group. The inhibition rate (%) was determined.

The results are shown in Tables 1 and 2.

In addition, damage coefficient and inhibition rate (
%) are shown in Table 3.

Table 1 Table 2 Table 3 Table 4 From the above results, it was confirmed that the dipolysaccharide obtained in the specific examples or examples has an inhibitory effect on hydrochloric acid-ethanol ulcers.

Experimental Example 2 The polysaccharide obtained in the specific example was orally administered to mice that had been fasted for 24 hours. After 50 minutes, add absolute ethanol to 02-
The mice were orally administered at the same dose as in Experimental Example 1, and the mice were sacrificed 1 hour later by tibial dislocation. The stomachs were removed, treated with formalin, and then incised along the human front. The inhibition rate (%) was determined by comparing with the control group.

The results are shown in Table 4.

From the above results, it was confirmed that the polysaccharide obtained in the specific example has an inhibitory effect on ethanol ulcers.

Experimental Example 3 The gamma polysaccharide obtained in the specific example was orally administered to mice that had been fasted for 48 hours. After 50 minutes, add 1M intomethane.
After dissolving with sodium hydroxide, diluted with physiological saline,
9 was administered intraperitoneally to xy/. Two hours later, 0.3M hydrochloric acid was orally administered at a dose of 0.27/mouse, and one hour later, the mice were sacrificed by tibial dislocation. The stomachs were removed, treated with formalin, and then incised along the human side. The length of gastric mucosal lesions was measured in a similar manner and the inhibition rate (%) was compared with the control group.
) was sought. The results are shown in Table 5.

Table 5 From the above results, it was confirmed that the polysaccharides obtained in the specific examples have an inhibitory effect on indomethane/hydrochloric acid gastric ulcers.

Experimental Example 4 A pyloric ligation ulcer was prepared according to the original report by Shay et al. That is, rats that had been exposed for 48 hours were subjected to laparotomy under ether anesthesia, and the pylorus was ligated. After laparotomy, the rats were left without food or water for 12 hours, the rats were sacrificed by dislocation of the tibial vertebrae, the stomachs were removed, and the gastric fluid stored in the stomachs was collected. Thereafter, 10 d of physiological saline was injected into the stomach, and then immersed in a 5% polymeric solution for 30 minutes to be slightly fixed. After that, an incision was made along the front of the person, and each ulcer that occurred on the stomach was measured.
Using the ulcer coefficient for each animal as the ulcer coefficient, determine the inhibition rate (%) by comparing with the control group. The polysaccharide obtained in the specific example was orally administered at 200 m9/kg 30 minutes before pylorus ligation.

In addition, the control group received only distilled water. As a result, the ulcer coefficient of the polysaccharide obtained in Example 2 was 1875, compared to 375 in the control group, and the inhibition rate was 500%.

In addition, the amount of gastric juice, acidity, pepsin activity, and exudate blood volume were measured for the collected gastric juice.

Acidity was determined by measuring free acidity (μ-/d) and total acidity (μ-/d) by the method of Ackerman et al.

Pepsin activity (L-tyrosine W9/J/hr
) uses bovine serum albumin as a substrate;
o) It was measured by the method of et al.

The amount of exuded blood (0, D,) is determined by the amount of noudoperoxidase (pseudoperox 1d) possessed by hemoglobin.
This was done by measuring the activity.

The results are shown in Table 6.

From the results shown in Table 6, item 1, it was confirmed that the polysaccharide obtained in the specific example suppresses the occurrence of pyloric ligation ulcer. In addition, although no changes were observed in the amount of secreted gastric juice, total acidity, free acidity,
All showed inhibitory effects on pepsin activity and red blood cell exudation.

As described above, polysaccharides A, B, C, D, E and F have anti-ulcer effects and are considered to be useful as anti-ulcer agents.

Next, the dosage and formulation of the polysaccharide disclosed in the present invention will be explained.

The polysaccharide disclosed in the present invention can be administered to animals and humans as is or together with a conventional pharmaceutical carrier. The dosage form is not particularly limited and may be selected as appropriate depending on the need. 3. Is Chudai the best way to achieve the desired effect as an oral drug?・
Depending on age, weight, and degree of disease, the weight of the polysaccharide for adults is usually 50,079 to 10/l. f-ru sutra [
] Agents include, for example, starch, lactose, sucrose, and ma.

2.1. It is manufactured using carpogynomethylcellulose, cornstarch, inorganic salts, etc. according to a conventional method.

In addition to the above-mentioned excipients, this type of preparation may include binders,
Disintegrants, surfactants, lubricants, fluidity promoters, flavoring agents,
Coloring agents, fragrances, etc. may be used. Specific examples of each are shown below.

゛Binder co-starch, dextrin, arahia gum powder, celadin,
Hydroquinopropyl starch, methylcellulose, sodium carboquinomethylcellulose, hydroquinopropylcellulose, crystalline cellulose, ethylcellulose, polyhinylpyrrolidone, macrogol.

L Disintegrant" Starch, hydroquine propyl starch, sodium carboxin methylcellulose, calcium carboxin methylcellulose, carboxin methylcellulose, low substituted hydroquinopropyl cellulose.

"Surfactant" Sodium lauryl sulfate, soybean lentin, sucrose fatty acid ester, polysorbate 80° [Lubricant] Talc, waxes, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate, Polyethylene glycol.

[Fluidity promoter] Light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate, magnenium silicate.

Furthermore, the polysaccharide disclosed in the present invention can be administered as a suspension, emulsion, syrup, or elixir, and these various dosage forms may contain flavorings and coloring agents. good.

In order to achieve the desired effect as a parenteral agent, the dosage varies depending on the age, weight, and severity of the disease of the author, but the amount of polysaccharide weight for an adult is usually 0.1 to 19% per day. Intravenous injection, intravenous drip, subcutaneous injection, or intramuscular injection are considered appropriate.

This parenteral preparation is manufactured according to a conventional method, and generally uses distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, polyethylene glycol, etc. as a diluent. I can do it. Furthermore, a bactericide, a preservative, and a stabilizer may be added as necessary. In addition, from the viewpoint of stability, this parenteral preparation may be filled into a vial or the like, then frozen, water removed by ordinary freeze-drying techniques, and a liquid preparation prepared from the freeze-dried product immediately before use. Furthermore, isotonizing agents, stabilizers, preservatives, soothing agents, etc. may be added as appropriate.

Other parenteral preparations include liquid preparations for external use, liniments such as ointments, suppositories for rectal administration, and the like, which are manufactured according to conventional methods.

The present invention will be explained in more detail by way of Examples below, but the present invention is not limited thereto.

Example 1 500 mg of the polysaccharide obtained in Example 2 was dissolved in water, and this solution was dissolved in DEAE-Sepharose CL-68 (HCO, -
) was added to a backed column (3.8×40σ), and a small amount of unadsorbed fraction was eluted by flowing water through the column as a solvent. Furthermore, the adsorbed fraction was eluted from this column with 0.1M ammonium hydrogen carbonate, then 0.3M ammonium hydrogen carbonate, and then further eluted with 05M ammonium hydrogen carbonate. This 0.5M ammonium bicarbonate elution fraction was dialyzed against distilled water, and the internal solution was freeze-dried Example 2 ■Corn starch 449 Crystalline cellulose 409 ■Calhodic methylcellulose calcium 59 ■Light silicic anhydride 059 ■Stearic acid mak 059 ■Compound obtained in Example 1 IC1i? Total
1009 According to the above recipe, ① to ② were mixed uniformly and compressed using a tablet machine to obtain 200~ tablets.

This tablet contains 20m9 of the compound obtained in Example 1, and adults should take 10 to 25 tablets in several doses per day.

By doing so, polysaccharide AI23m9 was obtained.

Example 3 ■Crystalline cellulose 84.5@■Macnenium stearate 0659■Calhoquinomethylcellulose carnoum 59 ■Specific example I compound 109 Total 1009 A part of ■ and ■ according to the above recipe was homogenized After mixing and compression molding, the mixture was pulverized, the remaining amounts of (1) and (2) were added and mixed, and compression molded using a tablet machine to obtain some tablets of 200π9.

These tablets contain 20 to 20 of the compounds obtained in Example 1, and are taken by adults in 10 to 25 tablets divided into several doses per day.

Example 4 Engineered crystalline cellulose 4959 210% human Nikin propino 1 Nanano 1. CI-Sueta, l-7°L solution 35z
3 Calphoginomekyl cellulose carnoum 59 ■Macunium stearinoate O9 ■Specific example 2 audience compound 10q Total 1009 Mix ■, ■, and 5; uniformly according to the above recipe, and dry by conventional method. and granulated using an extrusion granulator.
After drying and crushing, mix (2) and (T) and compress and mold using a tablet machine to obtain 200 pieces of tablets.

These tablets are coated with 2゜π9 of the f2 compound obtained in Example 2 and are gold-plated, and adults should take 10 to 25 tablets a day in several doses.

Example 5 Ecornstarch 3 = I, 59■゛Macnenoum stearate 509aj Power Sulfoquin Medilseno L, a-Skull/Rum D9T Light silicic anhydride 0.5g・5 Compound obtained in Example 3
+09 total 1009 According to the above recipe, ■ to ■ were mixed uniformly, compression molded using a compression molding machine, pulverized using a crusher, and sieved to obtain granules.

This granule I9 contains 100 to 100 mg of the compound obtained in Example 3, and is taken by adults 2 to 57 mg several times a day.

Example 6 - 1 item Cellulose 55〆, 210% human lokinob [7-bill cellulose eta,! -ru solution 359 Force Example 4 Obtained f = Compound -,,,,-,-j -09
00y 1-Note, 1"] ・Follow the recipe, mix 1 to 3 uniformly, add 1 to 5, pour out a portion, and granulate with a granulator.
(The granules were obtained by drying (-1 sieve).
Adults should take 1F'2 to 5ζ several times.

Example 7 ■Corn starch 8959 ■Light silicic anhydride 0.5 g ■F2 compound obtained in specific example 5 10y total 1009 According to the above recipe, ■~(3) were mixed uniformly, and 200
my was filled into a No. 2 capsule.

One capsule of this preparation contains 20 mg of the compound in Example 5 (1), and adults should take 10 to 25 capsules a day in several doses.

Example 8 ■ Soybean oil 59 ■ Distilled water for injection 89.59 ■ Soybean phospholipid 2.59 ■ Glycerin 2 g ■ One compound obtained in Example 1 19 Total amount
100g Dissolve ■ in ■ and ■ according to the above recipe, and add ■
The solutions of (1) and (2) were added and emulsified to obtain an injection.

Claims (7)

[Claims] (1) The following physical and chemical properties [1] Properties: white fibrous, [2] molecular weight: 63,000 [gel filtration chromatography], [3] specific optical rotation: [α]^2^3_D=+199.7 °
, [4] Constituent sugars: rhamnose, arabinose, xylose, mannose, galactose, glucose, galacturonic acid, [5] Unity: Shows unity by electrophoresis, gel filtration chromatography, high performance liquid chromatography, [6] ] Constituent sugar bonding mode: 4-linked galacturonic acid, 2,4-branched galacturonic acid as the main bonding mode, in addition to this, terminal arabinofuranose, terminal arabinopyranose, 4 or 5-linked arabinose, 3,4 or 3,5 branched arabinose, 4 or 5
linked xylose, terminal rhamnose, two-linked rhamnose,
3-linked rhamnose, 3,4-branched rhamnose, 2,4-branched rhamnose, terminal fucose, 4-linked glucose, terminal galactose, 4-linked galactose, 3-linked galactose, 4,6-branched galactose, terminal galacturonic acid, 3,
It is composed of 4- or 3,5-branched galacturonic acid. A polysaccharide with (2) The following physical and chemical properties [1] Properties: pale brown fibrous, [2] Molecular weight: 80,000-21,000, [high performance liquid chromatography] [3] Constituent sugars: mainly arabinose and galacturonic acid , small amounts of rhamnose, xylose, mannose, and glucose. An anti-ulcer agent whose active ingredient is a polysaccharide having (3) The following physical and chemical properties [1] Properties: White fibrous, [2] Molecular weight: 59,000, (gel filtration chromatography) [3] Constituent sugars: Mainly galacturonic acid, with small amounts of arabinose, galactose, Rhamnose, glucose and trace amounts of xylose, mannose. An anti-ulcer agent whose active ingredient is a polysaccharide having (4) The following physical and chemical properties [1] Properties: Light brown fibrous, [2] Molecular weight: 28,000, (gel filtration chromatography) [3] Constituent sugars: Mainly galacturonic acid, with small amounts of arabinose and galactose , rhamnose and trace amounts of xylose, glucose, and mannose. An anti-ulcer agent whose active ingredient is a polysaccharide having (5) The following physical and chemical properties [1] Properties: Light brown fibrous, [2] Molecular weight: 70,000 to 16,000 (gel filtration chromatography), [3] Constituent sugars: arabinose, glucose, galacturonic acid Mainly,
Small amounts of rhamnose and galactose. An anti-ulcer agent whose active ingredient is a polysaccharide having (6) The following physical and chemical properties [1] Properties: White fibrous, [2] Molecular weight: 36,000 (gel filtration chromatography), [3] Specific optical rotation: [α]^2^0_D=+120°, [
4] Constituent sugar: rhamnose, arabinose, galactose, galacturonic acid, [5] Unity: Shows unity by electrophoresis, gel filtration chromatography, high performance liquid chromatography, [6] Constituent sugar binding mode: 1, 5-linked arabinofuranose 1.4% Terminal galactose 2.7% Terminal galacturonic acid 2.7% 3,5-branched arabinofuranose 2.8% 2,4-branched rhamnose 2.2% 1,4-linked galacturonic acid 80. 0% 1,6-linked galactose 1.9% 1,4-linked galactose 4.2% 3,6-branched galactose 0.7% An anti-ulcer agent containing a polysaccharide as an active ingredient. (7) The following physical and chemical properties [1] Properties: White fibrous, [2] Molecular weight: 63,000, (gel filtration chromatography) [3] Specific rotation: [α]^2^3_D=+199.7 °
, [4] Constituent sugars: rhamnose, arabinose, xylose, mannose, galactose, glucose, galacturonic acid, [5] Unity: Shows unity by electrophoresis, gel filtration chromatography, high performance liquid chromatography, [6] ] Constituent sugar bonding mode: 4-linked galacturonic acid, 2,4-branched galacturonic acid as the main bonding mode, in addition to this, terminal arabinofuranose, terminal arabinopyranose, 4- or 5-linked arabinose, 3,4 or 3,5 branched arabinose, 4 or 5
linked xylose, terminal rhamnose, two-linked rhamnose,
3-linked rhamnose, 3,4-branched rhamnose, 2,4-branched rhamnose, terminal fucose, 4-linked glucose, terminal galactose, 4-linked galactose, 3-linked galactose, 4,6-branched galactose, terminal galacturonic acid, 3,
It is composed of 4- or 3,5-branched galacturonic acid. An anti-ulcer agent whose active ingredient is a polysaccharide having